IMMUNODEFICIENCY
Clinical trials for IMMUNODEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new IMMUNODEFICIENCY trials appear
Sign up with your email to follow new studies for IMMUNODEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a stem cell transplant fix a rare genetic immune disorder?
Disease control Recruiting nowThis study tests whether a stem cell transplant from a healthy donor can treat GATA2 deficiency, a rare genetic condition that weakens the immune system and raises the risk of leukemia. Participants aged 6 to 70 with GATA2 mutations will receive chemotherapy or radiation before t…
Matched conditions: IMMUNODEFICIENCY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a stem cell transplant tame VEXAS syndrome?
Disease control Recruiting nowThis study tests whether a stem cell transplant from a donor can help people with VEXAS syndrome, a rare autoinflammatory disease. Participants receive donor stem cells after drugs to prepare their bone marrow. The goal is to see if the transplant can reverse symptoms and allow p…
Matched conditions: IMMUNODEFICIENCY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New immune cell boost may shield kids from Post-Transplant infections
Disease control Recruiting nowThis study tests whether adding memory immune cells (CD45RO) to a stem cell transplant can help children fight off dangerous viral and fungal infections after the procedure. The transplant uses donor stem cells that have been stripped of certain cells to prevent graft-versus-host…
Matched conditions: IMMUNODEFICIENCY
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could longer or stronger antivirals beat COVID in vulnerable patients?
Disease control Recruiting nowThis study looks at whether giving a longer course (10 days instead of 5) or adding another antiviral (remdesivir) to the standard Paxlovid treatment helps immunocompromised people clear COVID-19 faster. About 256 adults with mild or no symptoms will be randomly assigned to diffe…
Matched conditions: IMMUNODEFICIENCY
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New trial aims to boost COVID-19 protection for vulnerable patients
Disease control Recruiting nowThis study is testing whether giving a longer course of the antiviral Paxlovid (10 days instead of 5) or combining it with another antiviral (remdesivir) helps immunocompromised people clear COVID-19 faster. About 256 participants with mild to moderate COVID-19 and weakened immun…
Matched conditions: IMMUNODEFICIENCY
Phase: PHASE2 • Sponsor: Calmy Alexandra • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Massive gene hunt aims to unlock secrets of immune disorders
Knowledge-focused Recruiting nowThis study is looking for the genes that cause certain immune system problems. Researchers want to understand why some people get sick and others don't, even in the same family. Up to 5,000 people with immune disorders and their relatives will give blood or cheek cell samples for…
Matched conditions: IMMUNODEFICIENCY
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New study to reveal hidden weaknesses in vaccines for Immune-Compromised patients
Knowledge-focused Recruiting nowThis study looks at how well vaccines against respiratory viruses (like flu or COVID-19) work in people with weakened immune systems, including those with blood cancers. Researchers will measure both antibody and T cell responses after vaccination. The goal is to understand why v…
Matched conditions: IMMUNODEFICIENCY
Sponsor: University of Cologne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Parkinson's drug may weaken immunity: new study investigates
Knowledge-focused Recruiting nowThis study looks at whether clozapine, a drug used to treat psychosis in Parkinson's disease, weakens the immune system over time. Researchers will measure immune markers in 24 patients before and after 6 and 12 months of treatment. The goal is to understand infection risks in th…
Matched conditions: IMMUNODEFICIENCY
Phase: PHASE4 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC